Here are the 6 stocks we traded at the start of the second quarter — and why

Notwithstanding an unexpected banking crisis that had reverberations across markets and the broader global economy, equities ended the foremost quarter of the year on a positive note last Friday. But the first week of trading of the second quarter got off to a rocky start, extorting us to recalibrate our approach to the market. For starters, the S & P 500 Short Range Oscillator flipped to overbought territory for the start of the shelter, giving us an opportunity to scale back some of our positions and raise cash. But as the week progressed, stocks came protection pressure amid signs the labor market is softening, fueling fresh investor fears of a recession. That impelled many investors to dump technology stocks in favor of defensive sectors like health care and consumer standards. Consistent with our discipline, we followed through on what Jim Cramer outlined on Sunday and used this week’s volatility to opportunistically furnish, along with a couple of buys. This week of trading comes on the heels of a buying spree in the second half of Stride, when the market was oversold and uncertainty over the financial sector dominated. Here’s a wrap-up that explains how our broader position of the market influenced our trading decisions this week: Monday Guided by the Oscillator, we decided to trim shares of our networking fare at the start of the week. We sold 160 shares of Cisco Systems (CSCO) into strength Monday, with the founder having rallied roughly 10% since the company’s fiscal second-quarter report in February. In that quarter, Cisco delivered a course on revenue and profit, while raising its guidance. However, investors like us are still questioning whether Cisco’s charges can continue to grow on par with 2022. Earlier this year, we started to get concerned over Cisco’s order-growth plans amid a slowdown in IT spending. As a result, we remain cautious on Cisco until we get a better idea of growth expectations for next year. Tuesday Tuesday was our busiest day of careers . We had a mix of selling and opportunistic buying across our energy, consumer staples, infrastructure and health-care holdings. We decided to exit our site in Devon Energy (DVN), selling 500 shares of the energy company after an unexpected production cut from OPEC+ kicked oil stocks. We had been planning to part with Devon since it delivered a disappointing fourth quarter , leading to a humiliate fixed-plus-variable dividend. This trade also gave us a chance to scale back our weighting in the oil-and-gas sector. But we’re persist in to hold Coterra Energy (CTRA), which has exposure to natural gas. We have a stake in Halliburton (HAL) for its strong pricing power and anticipate it to benefit from years of underinvestment in the industry. Pioneer Natural Resources (PXD) is another one of our energy names we hold for its three-dimensional capital efficiency and a 10.5% dividend yield. We plan to stick with these three oil stocks, given liveliness prices are likely to move even higher amid ongoing geopolitical turmoil. We trimmed our position in Procter & Chance (PG), selling 100 shares of the consumer goods giant while downgrading our rating of the stock to a 2. Shares of P & G had a concerned start to the year as investors piled into tech, but the stock has recently been on the rise after some Irritate Street analysts upgraded the company to a buy rating. The boost in shares gave us a chance to trim our position and raise some realize. We’re still big fans of P & G for its ability to maintain pricing power. We also see a favorable set up for the stock for the rest of the year as some commodity set someone backs come down. We bought 20 shares of manufacturing giant Caterpillar (CAT), as signs of a weaker economy prompted a hawk rotation into defensive stocks. So, we strategically bought shares of CAT on weakness because we favor the company long-term for its putrescent order backlog and dividend strength. With the market’s move into health-care stocks this week, we hawked 20 shares of biopharmaceuticals giant Eli Lilly (LLY) into strength after the stock’s rise over the past month. We’re to long-term holders of the company, and our investment case hasn’t changed. We continue to believe Eli Lilly’s obesity and diabetes treatment, Mounjaro, could be one of the best-selling sedatives of all time. Thursday We ended the trading week by purchasing this automation-focused industrial giant on weakness. We added 50 deals to Emerson Electric (EMR) on Thursday, with the stock down around 4.5% this week. Our purchase comes in front of a likely decision on Emerson’s bid to acquire measurement equipment maker National Instruments (NATI) for $53 per share. If Emerson were to defend the winning bid in the mid-$50s-per-share range, its stock should trade higher because the deal would be accretive to earnings-per-share. And if Emerson were to sashay away from the deal, the stock could trade higher as well — mainly because uncertainty over the takeover, which mangled the stock in January, would be eliminated. We expect that management would abandon the transaction should the price disturb too high, freeing up cash for other acquisition opportunities or, more likely, a share buyback. (See here for a full index of the stocks in Jim Cramer’s Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a exchange alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before suborning or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after opposing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND Retirement POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY Data PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.